Eliem Therapeutics, Inc. (NASDAQ:ELYM – Get Free Report)’s share price dropped 3% during mid-day trading on Friday. The stock traded as low as $10.44 and last traded at $10.54. Approximately 654,057 shares traded hands during mid-day trading, an increase of 34% from the average daily volume of 486,688 shares. The stock had previously closed at $10.87.
Eliem Therapeutics Stock Down 3.3%
The firm has a market cap of $303.17 million, a price-to-earnings ratio of -19.23 and a beta of -0.39. The stock’s 50 day moving average is $13.44 and its 200 day moving average is $12.08.
Eliem Therapeutics Company Profile
Eliem Therapeutics, Inc is a biopharmaceutical company that historically focused on developing therapies for disorders associated with abnormal neuronal excitability, including neuropathic pain, epilepsy, depression, and anxiety. The company’s research programs were designed to address conditions affecting the central and peripheral nervous systems.
Eliem’s development pipeline included ETX-810, an oral prodrug of pregabalin intended to improve the delivery and therapeutic profile of an established treatment for neuropathic pain, and ETX-155, a GABA-A receptor positive allosteric modulator investigated for potential use in neurological and psychiatric disorders.
Featured Articles
- Five stocks we like better than Eliem Therapeutics
- Bloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
Receive News & Ratings for Eliem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eliem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
